NCT00123331View on ClinicalTrials.gov

Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

April 30, 2005

Conditions
Heart TransplantationRenal Failure
Interventions
DRUG

Cyclosporine discontinuation

DRUG

Rapamycin medication

Trial Locations (1)

D-69115

Medizinische Universitätsklinik, Kardiologie, Heidelberg

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Heidelberg University

OTHER

NCT00123331 - Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation | Biotech Hunter | Biotech Hunter